top of page

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK and WALTHAM, Mass., April 05, 2024 (GLOBE NEWSWIRE) — Dianthus Therapeutics, Inc. (“Dianthus”), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced that it granted equity awards on April 1, 2024, to six newly-hired, non-executive employees. The inducement grants were approved by the Company’s independent Compensation Committee and were made as material inducements to acceptance of employment with Dianthus in accordance with Nasdaq Listing Rule 5635(c)(4). Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aktuelle Beiträge

Alle ansehen

コメント


bottom of page